Evidence tier
Strong
Research weight
Citations
23 verified / 23
Classification
Vitamin
❝
What the evidence says. Multiple high-quality RCTs / meta-analyses with consistent effects.
What is Vitamin B12?
Vitamin B12 (Cobalamin) is a vitamin used for prevents anemia. NutriDex grades the human evidence as Strong. B12 is required for red-blood-cell formation, DNA synthesis, and neurological function. Deficiency causes anemia and potentially irreversible nerve damage, and is common in vegans, older adults, and people on metformin or acid-reducers. Supplementation cleanly reverses deficiency. In replete people, extra B12 does not boost energy despite marketing claims.
Purported Benefits
✓Prevents anemia
✓Nerve health
✓Energy (if deficient)
✓Cognitive maintenance
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Corrects deficiency (anemia/neuropathy)Cleanly reverses deficiency anemia and neuropathy; oral high-dose equals intramuscular for normalizing levels. | Strong | ↑ benefit · large | 5 |
| Lowers homocysteineMeta-analyses (16-21 RCTs) consistently lower homocysteine ~4-5 umol/L, dose-dependent; biomarker, not a clinical endpoint. | Strong | ↑ benefit · moderate | 3 |
| Cognition/memory in replete adultsMeta-analysis (9 RCTs, ~9,000) found no cognitive or mood benefit absent deficiency; benefit limited to deficient people. | Moderate | — no effect · negligible | 3 |
| Diabetic neuropathy symptomsMeta-analysis (6 RCTs, ~459) improved symptoms and pain but not objective vibration threshold; small trials. | Preliminary | ↑ benefit · small | 1 |
| Brain atrophy in MCI (with folate/B6)VITACOG RCT slowed atrophy only in those with high baseline homocysteine, and used a B-vitamin combo, not B12 alone. | Preliminary | ↑ benefit · moderate | 1 |
| Vascular event prevention (with B-vitamins)VITATOPS RCT (8,164 stroke/TIA pts) found B-vitamin combo did not reduce major vascular events despite lowering homocysteine. | Moderate | — no effect · negligible | 1 |
Dosing & Compounds
Typical Dose
2.4 µg/day RDA; deficiency corrected with high oral (500–1,000 µg) or injections.
Active Compounds
Safety & Cautions
Very safe; excess excreted. No established toxicity. Educational only — always check with your doctor or pharmacist before combining Vitamin B12 with any medicine.
Key Studies ★ 23 studies
Meta-analysis
Sohouli 2024 (meta-analysis)
✓ PubMed
Meta-analysis of 21 RCTs (n=1,625) found B12 supplementation lowered homocysteine by a pooled WMD of -4.15 umol/L (95% CI -4.86 to -3.45), with larger effects at higher doses (>500 ug/d) and longer duration.
Meta-analysis
Cureus 2024 (systematic review/meta-analysis)
✓ Full text
Pooled analysis of 9 RCTs (~9,000 participants) found B12 supplementation had no significant effect on cognitive memory (SMD -0.03) or depressive symptoms (SMD -0.01) in the general population, suggesting benefit is limited to deficient individuals.
Meta-analysis
Network meta-analysis 2024 (routes)
✓ Full text
Network meta-analysis (13 studies, 8 RCTs, 4,275 patients) found intramuscular, oral, and sublingual B12 all effectively raised B12 levels with no clinically significant difference between routes.
meta-analysis
Mortality dose-response meta-analysis 2024
✓ PubMed
Dose-response meta-analysis of 22 cohort studies (92,346 individuals, 10,704 deaths) found each 100 pmol/L higher serum B12 was associated with 4% higher all-cause mortality (HR 1.04, 95% CI 1.01-1.08) in the general population and 6% (HR 1.06, 95% CI 1.01-1.13) in older adults, with high concentrations >600 pmol/L linked to a 50% higher risk (HR 1.50, 95% CI 1.29-1.74).
systematic review
Cochrane pregnancy review 2024 (Finkelstein)
✓ Full text
Cochrane systematic review of 5 trials (984 pregnant women; 3 trials/609 women in meta-analysis) found B12 supplementation may reduce maternal B12 deficiency and raise B12 concentrations, but evidence was very uncertain and effects on miscarriage, neural tube defects, and child cognition could not be established.
Meta-analysis
Frontiers Pharmacol 2025
✓ Full text
Systematic review/meta-analysis of 16 studies (6,098 participants) found oral and sublingual B12 comparable to intramuscular injection, with a pooled serum cobalamin rise of +402.6 pg/mL (95% CI 293.6 to 511.5) and homocysteine reduction of -4.83 umol/L (95% CI -6.55 to -3.11), no significant difference by route (p=0.27).
Systematic review
Cureus 2025
✓ PubMed
Systematic review of 10 RCTs found B12 supplementation improved neurological symptoms in overt deficiency (oral comparable to IM), but produced no significant cognitive or neurological benefit in older adults with subclinical deficiency.
Meta-analysis
Mazur 2025
✓ PubMed
Meta-analysis of 16 studies (6098 participants): B12 supplementation raised serum cobalamin (pooled MD +402.6 pg/mL; 95% CI 293.6-511.5) and lowered homocysteine (MD -4.83 micromol/L; 95% CI -6.55 to -3.11), with no significant difference between oral, sublingual, and intramuscular routes (P=0.27 cobalamin; P=0.49 homocysteine).
Meta-analysis
Alzahrani 2024
✓ PubMed
Meta-analysis of 9 RCTs found vitamin B12 supplementation had no significant effect on cognitive memory function (standardized mean difference -0.03; 95% CI -0.07 to 0.01; P=0.18) or depressive symptoms (SMD -0.01; 95% CI -0.077 to 0.053; P=0.71) in the general population without overt deficiency.
Meta-analysis
Diabetic neuropathy meta-analysis 2022
✓ Full text
Meta-analysis of 6 RCTs (~459 patients) found B12 supplementation significantly improved neuropathic symptoms (p=0.03) and reduced pain (p<0.001) in diabetic neuropathy, but did not change objective vibration perception threshold.
Meta-analysis
Metformin B12 meta-analysis 2022
✓ Full text
Meta-analysis of 17 studies found B12 deficiency was significantly more common in metformin-treated type 2 diabetes patients (23.2%) than non-users (17.4%) (OR 2.95, 95% CI 2.18-4.00), supporting periodic B12 monitoring.
meta-analysis
Fracture/homocysteine meta-analysis 2021
✓ Full text
Systematic review and meta-analysis (prospective cohorts) found higher vitamin B12 levels associated with a modest ~4% lower fracture risk per 50 pmol/L increase (borderline significant), while elevated homocysteine was an independent fracture risk factor, with no consistent effect on bone mineral density.
Guideline
Delphi expert consensus 2024
✓ Full text
Delphi consensus of 42 international experts established agreed recommendations for diagnosis, treatment, and long-term management of adult B12 deficiency, endorsing both intramuscular and high-dose oral replacement.
Guideline
NICE NG239 2024
✓ Source
UK NICE guideline (published 6 March 2024) recommends not excluding B12 deficiency on the basis of absent anaemia or macrocytosis, and offering oral cobalamin first-line with escalation to intramuscular hydroxocobalamin if symptoms do not improve.
Cochrane review
Cochrane CD004655 2018
✓ Full text
Cochrane review of 3 RCTs (153 participants) concluded oral and intramuscular B12 have similar effects on normalising serum B12 levels, with oral treatment costing less (low-quality evidence).
Systematic review
Wang (Cochrane Review) 2018
✓ PubMed
Cochrane review of 3 RCTs (153 patients) found oral vitamin B12 (1000-2000 microg/d) achieves serum B12 normalization comparable to intramuscular injection for treating deficiency, at lower cost and with apparently similar safety (low/very-low quality evidence).
RCT
OptiAge B-vitamin bone RCT 2022
✓ Source
2-year RCT (205 randomized, 167 completed) of combined B-vitamins (folic acid 200 ug, B12 10 ug, B6 10 mg, riboflavin 5 mg) found no overall bone benefit, but significantly slowed bone mineral density decline at the total hip and femoral neck in the subgroup with lower baseline B12 status (B12 <246 pmol/L or MMA >=0.22 umol/L).
RCT
Smith (VITACOG) 2010
✓ PubMed
In 168 adults >70y with mild cognitive impairment, 24 months of high-dose folic acid (0.8 mg/d) + B12 (0.5 mg/d) + B6 (20 mg/d) slowed whole-brain atrophy: 0.76%/yr active vs 1.08%/yr placebo (P=0.001). Effect was homocysteine-dependent — in those with baseline tHcy >13 micromol/L atrophy was 53% lower with treatment.
RCT
VITATOPS Trial 2010
✓ PubMed
In 8164 patients with recent stroke/TIA, daily folic acid 2 mg + B6 25 mg + B12 0.5 mg vs placebo over median 3.4y did not significantly reduce the composite of stroke, MI, or vascular death (15% vs 17%; RR 0.91, 95% CI 0.82-1.00, P=0.05). B vitamins were safe but did not prevent recurrent major vascular events.
Review
Wolffenbuttel 2024 (review)
✓ PubMed
Authoritative review noting rising risk of B12 deficiency from low intake or impaired absorption, and that early prevention/treatment is essential to avoid irreversible neurological damage given unreliable diagnostic biomarkers.
Consensus
Clinical consensus
✓ Source
Supplementation fully prevents/corrects deficiency anemia and neuropathy.
Study
Vegan-diet studies
✓ Source
B12 supplementation essential to avoid deficiency on plant-based diets.
Study
Andrès 2004
✓ PubMed
High-dose oral B12 as effective as injections for many patients.